Mylan Announces Approval for Omeprazole Delayed-release Capsules

PITTSBURGH, Jun 2, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release Capsules, 10 mg and 20 mg strengths and tentative approval for the 40 mg strength.

Omeprazole Delayed-release Capsules is the generic version of AstraZeneca LP's Prilosec®.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through its three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc., as well as branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. We refer you to the risk factors and other disclosures contained in our periodic SEC filings. We undertake no duty to update our forward-looking statements, even though our situation may change in the future.

SOURCE: Mylan Laboratories Inc.

Mylan Laboratories Inc.
Kris King, 724/514-1800